Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ITO
|
|||
| Former ID |
DIB001908
|
|||
| Drug Name |
Rifaximin
|
|||
| Synonyms |
RCIFAX; Rifaximin (bioadhesive/ gastrointestinal extended release); Rifaximin (bioadhesive/ gastrointestinal extended release), Salix Pharmaceuticals
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
| Company |
Salix Pharmaceuticals Ltd
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C43H51N3O11
|
|||
| Canonical SMILES |
CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C
|
|||
| InChI |
1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1
|
|||
| InChIKey |
NZCRJKRKKOLAOJ-XRCRFVBUSA-N
|
|||
| CAS Number |
CAS 80621-81-4
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:75246
|
|||
| ADReCS Drug ID | BADD_D01938 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroidaceae
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Bacteroidaceae was increased after Rifaximin treatment at both week 2 and week 8. | |||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis and minimal hepatic encephalopathy | |||
| Description | The abundance of Bacteroides was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Bacteroides was increased after Rifaximin treatment at both week 2 and week 8. | |||
|
Studied Microbe: Bacteroides caccae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides caccae was decreased by Rifaximin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Rifaximin (adjusted p-values: 5.92E-06). | |||
|
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Rifaximin (adjusted p-values: 2.64E-05). | |||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides ovatus was decreased by Rifaximin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides thetaiotaomicron was decreased by Rifaximin (adjusted p-values: 2.08E-05). | |||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Rifaximin (adjusted p-values: 1.32E-06). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Rifaximin (adjusted p-values: 2.30E-06). | |||
|
Studied Microbe: Bacteroides xylanisolvens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides xylanisolvens was decreased by Rifaximin (adjusted p-values: 4.93E-07). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Rifaximin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Rifaximin (adjusted p-values: 2.73E-07). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Rifaximin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Prevotella
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Hepatic encephalopathy | |||
| Description | The abundance of Prevotella was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Rifaximin (adjusted p-values: 1.58E-03). | |||
|
Studied Microbe: Rikenella
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Ankylosing spondylitis | |||
| Description | The abundance of Rikenella was decreased by Rifaximin (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis and minimal hepatic encephalopathy | |||
| Description | The abundance of Bifidobacterium was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bifidobacterium adolescentis was decreased by Rifaximin (adjusted p-values: 1.72E-05). | |||
|
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bifidobacterium longum was decreased by Rifaximin (adjusted p-values: 5.04E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Rifaximin (adjusted p-values: 2.74E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Eggerthella lenta
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eggerthella lenta was decreased by Rifaximin (adjusted p-values: 5.28E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Enterobacter
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis and minimal hepatic encephalopathy | |||
| Description | The abundance of Enterobacter was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Escherichia coli ED1a
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli ED1a was decreased by Rifaximin (adjusted p-values: 5.88E-06). | |||
|
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli IAI1 was decreased by Rifaximin (adjusted p-values: 7.52E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Anaerostipes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Anaerostipes was increased after Rifaximin treatment at week 2. | |||
|
Studied Microbe: Anaerostipes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Anaerostipes was decreased after Rifaximin treatment at week 8. | |||
|
Studied Microbe: Anaerotruncus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Anaerotruncus was decreased after Rifaximin treatment at week 2. | |||
|
Studied Microbe: Anaerotruncus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Anaerotruncus was increased after Rifaximin treatment at week 8. | |||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Rifaximin (adjusted p-values: 1.28E-05). | |||
|
Studied Microbe: Butyricicoccus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Ankylosing spondylitis | |||
| Description | The abundance of Butyricicoccus was decreased by Rifaximin (p < 0.05). | |||
|
Studied Microbe: Clostridioides difficile
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridioides difficile was decreased by Rifaximin (adjusted p-values: 1.84E-03). | |||
|
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis and minimal hepatic encephalopathy | |||
| Description | The abundance of Clostridium was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridium perfringens was decreased by Rifaximin (adjusted p-values: 5.51E-07). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Rifaximin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Rifaximin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Enterocloster bolteae was decreased by Rifaximin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Eubacteriales Family XIII. Incertae Sedis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Eubacteriales Family XIII. Incertae Sedis was decreased after Rifaximin treatment at week 2. | |||
|
Studied Microbe: Eubacteriales Family XIII. Incertae Sedis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Eubacteriales Family XIII. Incertae Sedis was increased after Rifaximin treatment at week 8. | |||
|
Studied Microbe: Eubacterium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis and minimal hepatic encephalopathy | |||
| Description | The abundance of Eubacterium was increased by Rifaximin. | |||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Rifaximin (adjusted p-values: 7.03E-06). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Rifaximin (adjusted p-values: 1.66E-04). | |||
|
Studied Microbe: Flavonifractor
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Ankylosing spondylitis | |||
| Description | The abundance of Flavonifractor was increased by Rifaximin (p < 0.05). | |||
|
Studied Microbe: Lachnospiraceae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis and minimal hepatic encephalopathy | |||
| Description | The abundance of Lachnospiraceae was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Lachnospiraceae incertae sedis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Ankylosing spondylitis | |||
| Description | The abundance of Lachnospiraceae incertae sedis was increased by Rifaximin (p < 0.05). | |||
|
Studied Microbe: Lacrimispora saccharolytica
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Lacrimispora saccharolytica was decreased by Rifaximin (adjusted p-values: 3.60E-07). | |||
|
Studied Microbe: Lactonifactor
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Lactonifactor was decreased after Rifaximin treatment at week 2. | |||
|
Studied Microbe: Lactonifactor
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Lactonifactor was increased after Rifaximin treatment at week 8. | |||
|
Studied Microbe: Oscillibacter
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Oscillibacter was decreased after Rifaximin treatment at week 2. | |||
|
Studied Microbe: Oscillibacter
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Oscillibacter was increased after Rifaximin treatment at week 8. | |||
|
Studied Microbe: Peptococcaceae
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Peptococcaceae was decreased after Rifaximin treatment at week 2. | |||
|
Studied Microbe: Peptococcaceae
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Peptococcaceae was increased after Rifaximin treatment at week 8. | |||
|
Studied Microbe: Peptostreptococcus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis and minimal hepatic encephalopathy | |||
| Description | The abundance of Peptostreptococcus was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Rifaximin (adjusted p-values: 1.88E-05). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Rifaximin (adjusted p-values: 1.90E-04). | |||
|
Studied Microbe: Ruminococcus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis and minimal hepatic encephalopathy | |||
| Description | The abundance of Ruminococcus was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Rifaximin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus gnavus was decreased by Rifaximin (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Rifaximin (adjusted p-values: 8.28E-05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Fusobacteriales | ||||
|
Studied Microbe: Fusobacterium
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Hepatic encephalopathy | |||
| Description | The abundance of Fusobacterium was not significantly changed by Rifaximin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis and minimal hepatic encephalopathy | |||
| Description | The abundance of Enterococcus was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Hepatic encephalopathy | |||
| Description | The abundance of Lactobacillus was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Lactobacillus paracasei
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Lactobacillus paracasei was decreased by Rifaximin (adjusted p-values: 8.07E-07). | |||
|
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis and minimal hepatic encephalopathy | |||
| Description | The abundance of Streptococcus was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Hepatic encephalopathy | |||
| Description | The abundance of Streptococcus was decreased by Rifaximin. | |||
|
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Streptococcus parasanguinis was decreased by Rifaximin (adjusted p-values: 5.51E-07). | |||
|
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Streptococcus salivarius was decreased by Rifaximin (adjusted p-values: 8.56E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Pasteurellales | ||||
|
Studied Microbe: Haemophilus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Hepatic encephalopathy | |||
| Description | The abundance of Haemophilus was not significantly changed by Rifaximin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Megasphaera
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Hepatic encephalopathy | |||
| Description | The abundance of Megasphaera was not significantly changed by Rifaximin. | |||
|
Studied Microbe: Veillonella
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Hepatic encephalopathy | |||
| Description | The abundance of Veillonella was decreased by Rifaximin. | |||
|
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Veillonella parvula was decreased by Rifaximin (adjusted p-values: 1.73E-04). | |||
|
Studied Microbe: Veillonellaceae
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Cirrhosis | |||
| Description | The abundance of Veillonellaceae was decreased by Rifaximin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Akkermansia muciniphila was decreased by Rifaximin (adjusted p-values: 5.51E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Bacteroidales
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Bacteroidales was increased after Rifaximin treatment at both week 2 and week 8. | |||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Bacteroidetes was increased after Rifaximin treatment at both week 2 and week 8. | |||
|
Studied Microbe: Bacteroidia
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Common variable immunodeficiency | |||
| Description | The abundance of Bacteroidia was increased after Rifaximin treatment at both week 2 and week 8. | |||
| Studied Microbe: Clostridium cluster XIVa | [6] | |||
| Abundance Change | Decrease | |||
| Experimental Species | Mice | Experimental Sample | Faeces | |
| Disease or Condition | Ankylosing spondylitis | |||
| Description | The abundance of Clostridium XlVa was decreased by Rifaximin (p < 0.05). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01654939) Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease. U.S. National Institutes of Health. | |||
| REF 2 | Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency. Sci Rep. 2019 Jan 17;9(1):167. | |||
| REF 3 | Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8(4):e60042. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol. 2017 Dec 21;23(47):8355-8366. | |||
| REF 6 | Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice. Front Cell Infect Microbiol. 2019 Mar 4;9:44. | |||
| REF 7 | Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014 May;60(5):940-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.